Archive - Trust the Evidence

Story of Influenza Antivirals: Part 31

The FDA and CDC split, compliharms and follow-up

Aug 15, 2023 •

and

Story of Influenza Antivirals: Part 35

The strange case of trial M76001

Aug 22, 2023 •

and

Story of Influenza Antivirals: Part 30

The claimed effect on prophylaxis, pre-and post-exposure

Aug 14, 2023 •

and

Story of Influenza Antivirals: Part 28

A shower of DVDs

Aug 7, 2023 •

and

Story of Influenza Antivirals: Part 20

The Council of Europe investigation of the handling of the influenza H1N1 “pandemic.”

Jun 14, 2023 •

and

Story of Influenza Antivirals: Part 38

Feb 7 •

and

Story of Influenza Antivirals: Part 33

Of missing populations and serious harms

Aug 17, 2023 •

and

Story of Influenza Antivirals: Part 27

Reflections on the term “placebo”

Jul 20, 2023 •

,

, and

Maryanne Demasi, PhD

Story of Influenza Antivirals: Part 36

Aug 23, 2023 •

and

Story of Influenza Antivirals: Part 32

Misleading meta-analysis of so-called individual- level data

Aug 16, 2023 •

and

Story of Influenza Antivirals: Part 29

The claimed effects on complications

Aug 10, 2023 •

and

Story of Influenza Antivirals: Part 34

Of missing serious harms

Aug 21, 2023 •

and

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts